Welcome to Glycemicon
Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a natural occurring tetrahydroxylated bile acid (THBA) in both humans and pets, which drives the formation of new fat cells to combat elevated blood glucose levels. The resulting greater number of smaller fat cells does not result in weight gain, but significantly improves the effectiveness of nutrient storage, increases insulin sensitivity and enables better control of blood sugar levels. The company has completed successful pre-clinical studies with THBA to demonstrate efficacy and a clean safety profile, and is running clinical trials for both humans and pets. The first nutraceutical product could be used either on its own or in co-administration with current anti-diabetic therapies. Founded in 2013 and financed mainly by private individuals, the company has raised CHF 7 million to date. As a spin-off company from the Federal Institute of Technology/ETH Zürich, we combine strong expertise in adipose tissue biology, diabetes and obesity with top-notch synthetic chemistry of natural products and small molecules. Close interactions with academic collaboration partners, such as the ETH, will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of prediabetes, type 2 diabetes and obesity. The name Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels which is the aim of every individual living with prediabetes and diabetes.
Nutraceuticals for managing prediabetes, diabetes and obesity